China approves 19 innovative drugs for commercial health insurance, opening new market opportunities for global and local ...

Companies are rolling out direct-to-patient services, which are selling drugs for weight loss and other uses.

Pfizer (PFE), and Johnson & Johnson (JNJ) secured spots on China's first innovative drug catalog for private insurance, ...

It’s about co-creating science.” The event highlighted pathogen research discoveries and pandemic prevention efforts from ...

Physician and science communicator Kristen Panthagani talks about why public trust in vaccines has fallen since the COVID-19 ...

An end-of-the-year slowdown has not been witnessed by the biopharma industry yet, and certainly not in the biotech deals ...

And other pharma news rounded up from around the Pharmalot campus, as told to you by the Pharmalittle newsletter ...

Country singer John Rich recounts a private dinner with the president, where Trump questioned why people at his rallies were ...

Nineteen novel drugs have been selected for inclusion in the first iteration of China's Commercial Health Insurance Innovative Drug Catalogue, portending potential access benefits as the program ga | ...

The company's BCMAxCD3 bispecific antibody Lynozyfic (linvoseltamab) got its first FDA approval as a fifth-line or later ...

Despite being among the great scientific breakthroughs of all time, vaccines are under fire as top US government officials ...

Mixed options sentiment in Pfizer (PFE), with shares up 4c, or 0.13%, near $26.07. Options volume roughly in line with average with 117k contracts ...